Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS11-001 + MEDI4736 in Cervical and HPV+ Head & Neck Cancer
NCT02291055Phase 2Terminated
- Sponsor
- Advaxis, Inc.
- Start
- Apr 2015
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of axalimogene filolisbac in Cervical Cancer (CC) and head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by Advaxis, Inc. Primary endpoints: Treatment Emergent Adverse Events up to 98 weeks, Progression Free Survival up to 146 weeks and 3 more. Started Apr 2015; status: terminated.
02
Drugs
axalimogene filolisbac
03
Conditions
Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02291055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291055.